News | November 6, 2024
Devyser proudly marks its 20th anniversary by celebrating a legacy of innovation, resilience, and growth in genetic diagnostics. Founded in 2004, Devyser began with a mission to revolutionize genetic testing, inspired by the personal experiences of our founders, who saw the need for more reliable and accessible diagnostics. Devyser has grown into a global leader from those early days, driven by our commitment to simplifying complex testing to benefit patients and healthcare providers worldwide.
Devyser is not only celebrating its 20th anniversary, but we are excited to announce the opening of our new facility in Stockholm, a key milestone in our expansion. This new site features expanded laboratories, a state-of-the-art warehouse, improved production workflows, and a dedicated studio to support continuous education and training. "Our new site reflects Devyser’s commitment to driving growth and innovation in genetic diagnostics," says Fredrik Alpsten, CEO of Devyser. "With this expansion, we can meet the growing global demand for our simple, fast, and accurate testing solutions for oncology, hereditary diseases, and post-transplant monitoring."
New office facts:
- 5000 m2 area, more than 3x the size of the old office.
- Lab space expanded from 300 m2 to 900 m2.
- 1,282 tons of CO2 were saved during construction, as the office was designed as a “Green Building”, per Svensk Miljöbyggnad’s Silver/Gold definition.
The additional space will enable us to support larger-scale production, streamline operations, and improve our R&D capabilities. Alongside expanded production and R&D facilities, the new site will serve as a hub for customer and distributor training through the Devyser Academy, including a studio and lecture room for continuously educating our global community of healthcare professionals.
Key milestones of our journey
Throughout our 20-year journey, Devyser has achieved numerous milestones that reflect our dedication to advancing genetic diagnostics:
- 2004: The founding of Devyser in Stockholm with a mission to make genetic testing more accessible and accurate.
- Product innovations: Our pioneering NGS products, particularly for post-transplant monitoring, have redefined patient care by offering precise and efficient testing solutions, improving outcomes in critical areas.
- 2014: The expansion into Italy, marked Devyser’s first major international subsidiary, establishing our approach to customer-centric diagnostics on a global scale.
- Going public in December 2021: This milestone reinforced Devyser’s position as a trusted leader in the diagnostics industry, broadening our reach and resources.
- Opening of Devyser Genomic Laboratories: Opening of the U.S. lab in Atlanta in 2023, our first step toward bringing advanced diagnostic services closer to U.S. healthcare providers and patients.
- 2024: The opening of our new site in Stockholm amplifies our production, R&D, and educational capabilities and provides a robust foundation for our next growth phase.
A legacy of innovation
Since our inception, Devyser has been guided by three core values: simplicity, relevance, and empathy. Our commitment to these principles has enabled us to develop solutions that streamline diagnostic processes, empowering clinicians with efficient tools that produce precise results. An unwavering dedication to patient-centered innovation fuels our expansion and continuous advancements. "This new space allows us to scale our operations, enhance product development, and continue delivering innovative solutions to meet the evolving needs of our customers," adds Fredrik Alpsten.
As we look to the future, Devyser is focused on leveraging new technologies and expanding our global presence to make high-quality diagnostics accessible to even more patients worldwide. With a dedicated team and a strong foundation, we’re excited about the possibilities and confident in our ability to lead in genetic diagnostics for years to come.
Here’s to the next chapter of Devyser’s journey—one that promises to bring groundbreaking advancements, a commitment to quality, and a continued focus on making a meaningful difference in patient care.
